Big Data for Pharmacovigilance2019-09-23T10:07:31+00:00

Project Description

Big Data for Pharmacovigilance Conference

Conference overview

Location: BMA House, London

Date: 11 – 12 September 2019

Join industry leaders for the second conference on big data for pharmacovigilance

The scale of available health data is increasing rapidly and as the age of Big Data is established, and following the success of the first event, we will be holding the second “Big Data for Pharmacovigilance Conference”.

Pharmacovigilance is increasingly characterised by extremely large data sets from populations, individuals, disease registries, social media, pharmacogenomics and more. While big data can be messy, efforts are underway to establish strategies for ordering and structuring the data in order to put it to the best use in pharmacovigilance and ultimately public health.

The published summary of our 2018 Big Data conference is available here:

2018 Big Data Conference summary

The published summary of our 2018 Big Data conference is available here:

Who should attend?

  • Staff from Pharma, academia and regulators with an interest in Big Data
  • Those working in drug safety or an allied discipline with an interest in electronic health records, linking data, data protection, transparency and reproducibility, natural language processing, the OMOP Common Data Model, real world evidence, etc
  • Those who wish to learn about Big Data and/ or contribute to the discussion on how PV should harness Big Data

Key topics

  • The findings of the HMA-EMA Joint Big Data task force
  • Lessons learned in developing and deploying machine learning for pharmacovigilance
  • Realising the full potential of artificial intelligence in big populations
  • Linking genetic information with clinical data
  • Update on EHDEN: the European Health Data & Evidence Network
  • Recent advances in Digital Epidemiology
  • OpenPVSignal, a tool for electronic exploration of signal reports
  • Routine and emerging Big Data Strategies for Real World Evidence generation
  • De-identification: use of natural language processing to remove patient identifiers from case narratives
  • Development of MyStudies App
  • Where do we stand with Big Data?

Aims of the conference

  • To provide attendees with an overview of the current status of Big Data for pharmacovigilance
  • To explain machine learning and how it is being developed and deployed
  • To allow attendees to gain an understanding of artificial intelligence in big populations
  • To provide with an update on the findings of the HMA-EMA Joint Big Data task force
  • To explore how genetic information can be linked with clinical data
  • To provide updates on EHDEN, digital epidemiology, the OpevPVSignal tool and MyStudies App
  • To explore routine and emerging Big Data Strategies for Real World Evidence generation

Download Conference Programme

Click here to download the programme



Cost Per Delegate:

£800 + VAT Academic

(Academic Units, Public Sector Organisations, Registered Charities)


£1000 + VAT Standard

(Standard Registration)

Registration fee includes lunch, refreshments and electronic access to all conference materials.

Booking options



“Great audience and very good presentations”

Big Data Delegate 2019

“Very well organised and excellent talks”

Big Data Delegate 2019

“Broad coverage of diverse aspects of issue”

Big Data Delegate 2018

“Very good range of speakers providing a diverse coverage of the topic”

Big Data Delegate 2019

“Excellent topics at the forefront of this newly emerging area”

Big Data Delegate 2018

Contact Info

Drug Safety Research Unit Bursledon Hall, Blundell Lane, Southampton, SO31 1AA, U.K.

Phone: +44 (0)23 80 40 86 00

Recent Posts